These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28526184)

  • 21. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
    Ferrannini E; Mark M; Mayoux E
    Diabetes Care; 2016 Jul; 39(7):1108-14. PubMed ID: 27289126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the EMPA-REG Trial for Clinical Care and Research.
    Stamatouli AM; Inzucchi SE
    Curr Diab Rep; 2016 Dec; 16(12):131. PubMed ID: 27812962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
    [No Abstract]   [Full Text] [Related]  

  • 31. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
    Alzaid A
    Diabetes Technol Ther; 2017 Jun; 19(6):324-327. PubMed ID: 28300428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EMPA-REG - the "diuretic hypothesis".
    McMurray J
    J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Zinman B; Fitchett D; Wanner C; Ferrannini E; Schumacher M; Schmoor C; Ohneberg K; Johansen OE; George JT; Hantel S; Bluhmki E; Lachin JM
    Diabetes Care; 2018 Feb; 41(2):356-363. PubMed ID: 29203583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Scheen AJ
    Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
    Abdul-Ghani M; Del Prato S; Chilton R; DeFronzo RA
    Diabetes Care; 2016 May; 39(5):717-25. PubMed ID: 27208375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.